Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients
2024-518226-32-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupropion and escitalopram in major depressive disorder (MDD) (3 arms), sponsored by Medical University of Vienna. Primary endpoint: Reward-specific changes of dopamine synthesis. Planned start Jan 2025; status: authorised.
02
Drugs
bupropionescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-518226-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518226-32-00.